Mabpharm Stock

Mabpharm EBIT

The EBIT of Mabpharm (2181.HK) as of Aug 6, 2026 is 5.43 M CNY. In the previous year, EBIT was -117.91 M CNY — a change of -104.61% (higher).

EBIT

5.43 MCNY

YoY

-104.61%

Last updated:

In 2026, Mabpharm's EBIT was 5.43 M CNY, a -104.61% increase from the -117.91 M CNY EBIT recorded in the previous year.

The Mabpharm EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M CNY)
Date
EBIT (M CNY)
Jan 1, 2021
-297.52 base
Jan 1, 2022
-226.25 base
Jan 1, 2023
-199.78 base
Jan 1, 2024
-117.91 base
Jan 1, 2025
5.43 base
Jan 1, 2026 (e)
-89.64 base
Jan 1, 2027 (e)
-89.64 base
Jan 1, 2028 (e)
-266.11 base
YEAREBIT (M CNY)
2028 est -266.11
2027 est -89.64
2026 est -89.64
2025 5.43
2024 -117.91
2023 -199.78
2022 -226.25
2021 -297.52
2020 -216.20
2019 -230.76
2018 -138.96
2017 -51.52
Access this data via the Eulerpool API

Mabpharm Revenue

Mabpharm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
82.88 M CNY
-297.52 M CNY
-291.74 M CNY
Jan 1, 2022
55.92 M CNY
-226.25 M CNY
-210.62 M CNY
Jan 1, 2023
87.16 M CNY
-199.78 M CNY
-209.36 M CNY
Jan 1, 2024
258.23 M CNY
-117.91 M CNY
-127.95 M CNY
Jan 1, 2025
730.71 M CNY
5.43 M CNY
64.62 M CNY
Jan 1, 2026 (e)
129.69 M CNY
-89.64 M CNY
-250.58 M CNY
Jan 1, 2027 (e)
129.69 M CNY
-89.64 M CNY
-308.09 M CNY
Jan 1, 2028 (e)
385.00 M CNY
-266.11 M CNY
-295.77 M CNY

Mabpharm Margins

Mabpharm stock margins

The Mabpharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mabpharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mabpharm.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
79.76 %
-358.97 %
-352.00 %
Jan 1, 2022
72.50 %
-404.61 %
-376.66 %
Jan 1, 2023
86.32 %
-229.21 %
-240.19 %
Jan 1, 2024
84.96 %
-45.66 %
-49.55 %
Jan 1, 2025
82.87 %
0.74 %
8.84 %
Jan 1, 2026 (e)
82.87 %
-69.12 %
-193.21 %
Jan 1, 2027 (e)
82.87 %
-69.12 %
-237.55 %
Jan 1, 2028 (e)
82.87 %
-69.12 %
-76.82 %

Mabpharm Stock analysis

What does Mabpharm do? Mabpharm Ltd is a biopharmaceutical company based in Suzhou, China. The company was founded in 2009 and specializes in the development and production of monoclonal antibodies. The business model of Mabpharm is to develop, produce, and sell high-quality biological drugs worldwide. The company works closely with customers to understand their needs and provide customized solutions. Mabpharm is divided into different divisions, each specialized in producing specific products. The main ones are oncology, immunology, cardiology, and infectious diseases. Each division offers a portfolio of products tailored to the needs of patients. In the field of oncology, Mabpharm offers a range of monoclonal antibodies that can be used to treat cancer. This includes therapies for breast cancer, gastric cancer, colorectal cancer, and lung cancer. The products have all been developed in collaboration with renowned partners worldwide and undergo rigorous clinical testing before being brought to market. Mabpharm's immunology division focuses on developing drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The products in this division have been specifically designed to regulate the immune system and suppress inflammation symptoms. The cardiology division of Mabpharm is dedicated to the development of drugs for the prevention and treatment of cardiovascular diseases. The products include antibodies for the treatment of lipid metabolism disorders and blood clots. Mabpharm's cardiovascular products also include a cholesterol-lowering medication that helps prevent heart attacks and strokes. In the infectious diseases division, Mabpharm has developed products for the treatment of hepatitis B and hepatitis C. These can reduce viral load and improve liver function. Furthermore, Mabpharm is also involved in the development of vaccines against COVID-19. Mabpharm has become a leading provider of monoclonal antibodies and biological drugs in China and internationally. The company works closely with academics and researchers to find innovative solutions and stay up to date with the latest scientific advancements. In conclusion, Mabpharm is an innovative company specializing in the research and development of biological drugs of all kinds. The company has a wide range of products that have been developed to meet the needs of patients worldwide. Mabpharm has emerged as a key player in the global market for biological drugs in recent years and is a company to watch when it comes to the future of biotechnology. Mabpharm is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Mabpharm's EBIT

Mabpharm's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Mabpharm's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Mabpharm's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Mabpharm’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Mabpharm stock

EBIT of Mabpharm is 5.43 M CNY in 2026.

EBIT of Mabpharm changed from -117.91 M CNY to 5.43 M CNY, representing a -104.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Mabpharm since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Mabpharm historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Mabpharm

All Key Metrics — Mabpharm